Abstract

Standard treatments for ischemic stroke are intravenous thrombolysis and endovascular recanalization. In the acute phase (<4.5 hours) only 3.2% to 5.2% of ischemic stroke patients are eligible for intravenous thrombolysis. Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into different types of cells that produce potential regenerative therapeutics in stroke patients. MSCs will secrete secretomes that contain growth factors, chemokines, cytokines, metabolites and bioactive lipids. Secretome promote production of CD31 and Vascular Endothelial Growth Factor (VEGF). Neurogenesis and angiogenesis effect from CD31 and VEGF cause brain cell regeneration and neurological improvement. This study analyzes the effect of 150 µl SH-MSCs injection toward CD31 and VEGF expression in rats with ischemic stroke. The method used was laboratory true experimental post-test with only control group design and sample was taken with consecutive sampling. It uses 18 Rattus norvegicus and divided into sham, control and P1 (MCAO + 150 ul secretome) groups. Control and P1 group were made in stroke condition with Middle Cerebral Artery Occlusion methods by clamping Common Carotid Artery. Modified Neurological Severity Score (mNSS) used to measure neurological function improvement. Mean value of VEGF and CD31 expression in P1 higher than control group and mNSS in P1 lower than control group. Through the increases of VEGF and CD31 expressions, SH-MSCs can drive cell proliferation, neuron cell survival, angiogenesis, neurogenesis and blood-brain-barrier integrity recovery in the rats’ brains, so it improves clinical outcomes and neurological function in rats with ischemic stroke.